Candel Therapeutics Reports Shareholder Vote

TL;DR

Candel Therapeutics held a shareholder vote on June 26th, details to follow.

AI Summary

Candel Therapeutics, Inc. filed an 8-K on June 28, 2024, reporting on a matter submitted to a vote of its security holders on June 26, 2024. The filing does not disclose the specific outcome or details of the vote, only that it occurred.

Why It Matters

Shareholder votes can indicate significant corporate decisions or changes, such as board elections or major proposals, which are important for investors to monitor.

Risk Assessment

Risk Level: low — This filing is a procedural update regarding a shareholder vote and does not contain new financial or operational information that would immediately impact the company's risk profile.

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• June 26, 2024 (date) — Date of earliest event reported
• June 28, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq

Filing Documents

• cadl-20240626.htm (8-K) — 61KB
• 0000950170-24-078795.txt ( ) — 179KB
• cadl-20240626.xsd (EX-101.SCH) — 27KB
• cadl-20240626_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Candel Therapeutics, Inc., a Delaware corporation (the "Company"), held its Annual Meeting of Stockholders (the "Annual Meeting") on June 26, 2024. As of May 15, 2024, the record date for the Annual Meeting, there were 29,756,005 outstanding shares of the Company's voting common stock. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on May 30, 2024: (i) to elect three directors, Nicoletta Loggia, Ph.D., R.Ph., Christopher Martell, and Diem Nguyen, Ph.D., M.B.A., as Class III directors of the Company to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal ("Proposal 1") and (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"). The Company's stockholders elected each of the Class III director nominees, Nicoletta Loggia, Ph.D., R.Ph., Christopher Martell, and Diem Nguyen, Ph.D., M.B.A., recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes Nicoletta Loggia, Ph.D., R.Ph. 7,181,872 150,389 - 7,427,258 Christopher Martell 6,994,015 338,246 - 7,427,258 Diem Nguyen, Ph.D., M.B.A. 7,020,058 312,203 - 7,427,258 The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows: For Against Abstain 14,617,652 98,945 42,922 No other matters

View Full Filing

View this 8-K filing on SEC EDGAR